Opendata, web and dolomites

DiViNe SIGNED

Sustainable downstream processing of vaccines through incorporation of nanobiotechnologies : novel affinity ligands and biomimetic membranes

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 DiViNe project word cloud

Explore the words cloud of the DiViNe project. It provides you a very rough idea of what is the project "DiViNe" about.

prophylactic    data    combine    partnership    capture    expense    issue    platform    membranes    brings    first    drastic    commercial    rely    affinity    water    technological    biologics    cleantech    dose    economically    mostly    answers       bioproduction    market    recovery    poor    nanofitins    healthy    countries    tackle    innovations    ingredient    extreme    biomimetics    yields    borders    people    eliminations    structure    divine    environmental    vaccine    strategies    industry    thereby    separation    negative    broad    pressure    multiple    local    antibody    novartis    identical    glycoconjugates    nano    protein    sustainable    energy    biotechnology    viruses    laquo    protecting    saving    contaminant    antigens    recycling    custom    enveloped    biopharmaceuticals    positive    theses    aquaporin    environment    technically    acute    downstream    discarded    direct    amenable    purification    run    affordable    vaccines    sustainability    goods    lack    natures    inducing    raquo    context    ligands    sensitive   

Project "DiViNe" data sheet

The following table provides information about the project.

Coordinator
INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLOGICA 

Organization address
address: AVENIDA DA REPUBLICA QUINTO DO MARQUES
city: OEIRAS
postcode: 2781 901
website: www.ibet.pt

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Portugal [PT]
 Project website http://www.divineproject.eu
 Total cost 7˙632˙281 €
 EC max contribution 5˙790˙580 € (76%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
 Code Call H2020-LEIT-BIO-2014-1
 Funding Scheme IA
 Starting year 2015
 Duration (year-month-day) from 2015-03-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLOGICA PT (OEIRAS) coordinator 1˙663˙706.00
2    MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN DE (DARMSTADT) participant 1˙397˙000.00
3    AFFILOGIC FR (NANTES) participant 1˙146˙225.00
4    GLAXOSMITHKLINE VACCINES SRL IT (SIENA) participant 813˙999.00
5    AQUAPORIN AS DK (KOBENHAVN) participant 519˙400.00
6    GENIBET - BIOPHARMACEUTICALS SA PT (OEIRAS) participant 250˙250.00

Map

 Project objective

In the vaccine industry, downstream processing is of extreme importance. Prophylactic vaccines aim at protecting healthy people, so any contaminant has to be discarded with the most drastic measures. Such « negative » approach comes at the expense of the recovery of product : yields are poor, thereby inducing a high product cost. Processes are also complex, since they rely on multiple eliminations rather than on recovery of the unique product of interest. Technically, this is mostly due to the lack of specific capture systems that would allow direct, « positive » separation of the vaccine from its environment.Vaccines know no borders. For developing countries, the pressure on costs is even more acute, and local production is a way to try to reach the 1$ per dose target. In this context, water sustainability is a major issue, as it is a most sensitive ingredient in bioproduction. DiViNe will tackle theses cost and environmental issues with technological answers. The partners will combine two major Nano/biotechnology innovations to develop an integrated purification platform amenable to the different natures of vaccines : glycoconjugates, protein antigens and enveloped viruses. They will implement Nanofitins (novel affinity capture ligands) and Aquaporin-based membranes (energy-saving nano-biomimetics used in the cleantech industry), for a « positive » purification approach. High yields are expected (data from antibody purification with Nanofitins), at affordable cost of goods and with a sustainable approach of water recycling. Novartis Vaccines brings to the Consortium a broad range of targets, and identical strategies can be applied for biopharmaceuticals in general. The development custom affinity capture processes as a sustainable platform is therefore economically relevant, in a very large market. Beyond the technical partnership, the project is a first run for the partners to structure the platform as a commercial offer for downstream processing of biologics.

 Deliverables

List of deliverables.
Dissemination via Patent protecting (products, processes…), vaccines / bioproduction congresses (poster, presentation) and scientific articles Websites, patent fillings, videos etc. 2020-03-11 13:01:30
Commercial tools on platform for exploitation of results Websites, patent fillings, videos etc. 2020-03-11 13:01:37
Website : public part for dissemination + password-protected part for project management Websites, patent fillings, videos etc. 2020-03-11 12:10:52

Take a look to the deliverables list in detail:  detailed list of DiViNe deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DIVINE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DIVINE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.)

SHIKIFACTORY100 (2019)

Modular cell factories for the production of 100 compounds from the shikimate pathway

Read More  

BioRoboost (2018)

Fostering Synthetic Biology standardisation through international collaboration

Read More  

BioICEP (2020)

Bio Innovation of a Circular Economy for Plastics

Read More